Gainers

• Serina Therapeutics (AMEX:SER) shares increased by 41.4% to $1.81 during Wednesday's after-market session. The market value of their outstanding shares is at $14.4 million.
• Spectral AI (NASDAQ:MDAI) shares increased by 33.33% to $1.6. The market value of their outstanding shares is at $39.2 million.
• Forte Biosciences (NASDAQ:FBRX) stock moved upwards by 8.97% to $27.08. The market value of their outstanding shares is at $331.2 million.
• InflaRx (NASDAQ:IFRX) stock moved upwards by 8.1% to $0.95. The market value of their outstanding shares is at $61.8 million.
• Genenta Science (NASDAQ:GNTA) stock increased by 7.39% to $0.74. The company's market cap stands at $18.8 million.
• Lineage Cell Therapeutics (AMEX:LCTX) stock moved upwards by 5.33% to $1.58. The company's market cap stands at $363.9 million.

Losers

• Reviva Pharmaceuticals (NASDAQ:RVPH) stock fell 38.5% to $1.15 during Wednesday's after-market session. The company's market cap stands at $271.0 million.
• Bio Green Med Solution (NASDAQ:BGMSP) shares decreased by 15.18% to $2.46.
• Agilon Health (NYSE:AGL) stock declined by 11.41% to $0.52. The market value of their outstanding shares is at $254.7 million.
• Zhengye Biotechnology (NASDAQ:ZYBT) shares declined by 10.2% to $0.88. The market value of their outstanding shares is at $34.1 million.
• Pomdoctor (NASDAQ:POM) stock fell 8.84% to $0.35. The company's market cap stands at $48.9 million.
• Mobile-health Network (NASDAQ:MNDR) stock declined by 8.18% to $0.95. The market value of their outstanding shares is at $3.0 million. As per the news, the H1 earnings report came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.